Protect and strengthen democratic society today and for the future. Invest in AllSides
Protect and strengthen democratic society today and for the future. Invest in AllSides
Protect and strengthen democratic society today and for the future. Invest in AllSides

See How AllSides Rates Other Media Outlets

We have rated the bias of nearly 600 outlets and writers!
See some of the most popular below:

Want to see more?
Check out the AllSides Media Bias Chart, or go to our Media Bias Ratings page to see everything.

See How AllSides Rates Other Media Outlets

We have rated the bias of nearly 600 outlets and writers!
See some of the most popular below:

Want to see more?
Check out the AllSides Media Bias Chart, or go to our Media Bias Ratings page to see everything.

See How AllSides Rates Other Media Outlets

We have rated the bias of nearly 600 outlets and writers!
See some of the most popular below:

Want to see more?
Check out the AllSides Media Bias Chart, or go to our Media Bias Ratings page to see everything.

Invest in

Invest in

Invest in

What America Do We Want to Be?

Join Living Room Conversations, our civil dialogue partner, and America Indivisible for a nationwide conversation on April 13, Thomas Jefferson’s 276th birthday. "Reckoning with Jefferson: A Nationwide Conversation on Race, Religion, and the America We Want to Be" will be held via in-person and online video discussions. Sign up today!

What America Do We Want to Be?

Join Living Room Conversations, our civil dialogue partner, and America Indivisible for a nationwide conversation on April 13, Thomas Jefferson’s 276th birthday. "Reckoning with Jefferson: A Nationwide Conversation on Race, Religion, and the America We Want to Be" will be held via in-person and online video discussions. Sign up today!

What America Do We Want to Be?

Join Living Room Conversations, our civil dialogue partner, and America Indivisible for a nationwide conversation on April 13, Thomas Jefferson’s 276th birthday. "Reckoning with Jefferson: A Nationwide Conversation on Race, Religion, and the America We Want to Be" will be held via in-person and online video discussions. Sign up today!

Practical, engaging webinars designed to transform how you approach current events and facilitate productive classroom discussions.

The Art of Discussion - Civic Learning Week

Wednesday March 12, 2025 | 6:00 PM Eastern Time

Learn how to facilitate respectful dialogue across political and social divides using Mismatch, our platform for connecting students with diverse viewpoints.

Register for the webinar PD Benefits Page
 

Practical, engaging webinars designed to transform how you approach current events and facilitate productive classroom discussions.

The Art of Discussion - Civic Learning Week

Wednesday March 12, 2025 | 6:00 PM Eastern Time

Learn how to facilitate respectful dialogue across political and social divides using Mismatch, our platform for connecting students with diverse viewpoints.

Register for the webinar PD Benefits Page
 

Practical, engaging webinars designed to transform how you approach current events and facilitate productive classroom discussions.

The Art of Discussion - Civic Learning Week

Wednesday March 12, 2025 | 6:00 PM Eastern Time

Learn how to facilitate respectful dialogue across political and social divides using Mismatch, our platform for connecting students with diverse viewpoints.

Register for the webinar PD Benefits Page
 

See How AllSides Rates Other Media Outlets

We have rated the bias of nearly 600 outlets and writers!

See some of the most popular below:

Want to see more?

Check out the AllSides Media Bias Chart, or go to our Media Bias Ratings page to see everything.

See How AllSides Rates Other Media Outlets

We have rated the bias of nearly 600 outlets and writers!

See some of the most popular below:

Want to see more?

Check out the AllSides Media Bias Chart, or go to our Media Bias Ratings page to see everything.

See How AllSides Rates Other Media Outlets

We have rated the bias of nearly 600 outlets and writers!

See some of the most popular below:

Want to see more?

Check out the AllSides Media Bias Chart, or go to our Media Bias Ratings page to see everything.

 

 

 

Support AllSides

Please consider becoming a sustaining member or making a one-time donation to help keep AllSides online.

Become a Sustaining Member

Make a one-time donation.

Support AllSides

Please consider becoming a sustaining member or making a one-time donation to help keep AllSides online.

Become a Sustaining Member

Make a one-time donation.

Support AllSides

Please consider becoming a sustaining member or making a one-time donation to help keep AllSides online.

Become a Sustaining Member

Make a one-time donation.

A controversial study that promoted hydroxychloroquine, an antimalarial drug, as a treatment for Covid-19 has officially been withdrawn.

On Tuesday, Elsevier, a Dutch academic publishing company which owns the International Journal of Antimicrobial Agents, issued the retraction of the March 2020 study, saying ā€œconcerns have been raised regarding this article, the substance of which relate to the articles’ adherence to Elsevier’s publishing ethics policies and the appropriate conduct of research involving human participantsā€.

The paper was retracted due to ethical and methodological issues. One of the most notable scientific papers that first popularized hydroxychloroquine as a COVID-19 treatment was retracted from its journal due to ethical and methodological issues. Retractions in scientific journals are rare and typically undergo an extensive investigative process. These retractions have been known to negatively affect the potential future employment, funding and reputation of researchers involved.

Thousands Of Children Prescribed Ivermectin Or Hydroxychloroquine For COVID: Study Authored by Zachary Stieber via The Epoch Times, Doctors prescribed ivermectin or hydroxychloroquine more than 4,400 times to children with COVID-19 during periods of time when the drugs were not recommended against the illness by authorities, according to a new study. Doctors issued 813 prescriptions of hydroxychloroquine to minors with COVID-19 after the Pediatric Infectious Diseases Society on Sept. 12, 2020, advised against using hydroxychloroquine outside of a clinical trial, researchers found.

Is hydroxychloroquine a generally safe drug?

The politically charged atmosphere surrounding the drug in the context of COVID-19 can present a distorted picture. But the best evidence suggests that it has few adverse effects, although it does present some risks for patients with heart conditions.

Dr. Alieta Eck, who prescribed hydroxychloroquine for her patients who had COVID-19 symptoms, was confident the drug was safe.

"My feeling was that it was not going to do any harm, which is true. It’s a very safe medicine," said Eck, an internist in New Jersey.

A trial investigating the drug hydroxychloroquine as a preventative treatment against Covid-19 may never find out if it's effective, say scientists involved.

Controversy around the drug - touted by President Trump and the subject of online misinformation - is stopping completion of the trial, they say.

It is ineffective in hospitalised patients, but investigators hope it might work if given earlier on.

Hospitals have pulled out of the trial.

The Oxford University-led trial is aiming to enrol 40,000 frontline workers around the world.

A Rasmussen Reports survey of 1,000 American adults conducted in April found that 53 percent of Republicans were willing to take anti-malarial hydroxychloroquine to treat COVID-19, while only 18 percent of Democrats were willing to try it.

The utter arbitrariness of how public opinion on scientific questions has fractured along partisan divides reveals something rotten at the core of the national conversation.